Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crohn’s/Colitis Foundation Launches “IBD Plexus”; Data-Linking Project Is Step Towards Personalized Therapy

This article was originally published in RPM Report

Executive Summary

The Crohn’s and Colitis Foundation of America is working on a platform to aggregate clinical, biosample and derived “omic” data across multiple cohorts. That’s worth watching as another step in the increasingly sophisticated and ambitious efforts by disease advocacy groups to collect, process and share data in specific conditions.

You may also be interested in...



Precision Medicine Is Precisely Right Theme For Biopharma: Impact Of Therapy—Not Cost—Is Focus

A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.

Is There a Draft In Here? 21st Century Cures Legislation Stumbles At The Starting Line

The House Energy & Commerce Committee released its eagerly awaited first draft of potential legislation to improve the climate for innovation in the US. Or did it? The unexpectedly partisan reaction is a sign of how far the process still has to go – but the overall pro-innovation focus is likely to carry through.

Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan

US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel